Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium bifidum BBi32
- Development stage
- Preclinical
- Lead developer
- Wecare Probiotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Bifidobacterium bifidum BBi32** is a specific strain of the species Bifidobacterium bifidum, a **Gram-positive, non-spore-forming, anaerobic actinobacterium** commonly used as a probiotic[3][1]. B. bifidum strains are widely recognized for their ability to colonize the gastrointestinal tract and confer health benefits such as suppression of pathogenic microorganisms, modulation of the immune system, enhancement of intestinal barrier function, and reduction of inflammation[3][1][5]. The BBi32 strain is presumed to share the hallmark features of its species, including strong **adhesion to intestinal cells, immune modulation, and the potential to ameliorate symptoms of gastrointestinal disorders** such as irritable bowel syndrome, large bowel dysfunctions, and inflammatory bowel conditions[3][7]. It may also possess mechanisms that protect the intestinal epithelium and contribute to establishing a balanced gut microbiota, especially in infants and individuals with disrupted microbiota[3][1][7]. While specific proprietary or clinical data for the BBi32 strain is not present in the available results, it is classified as a live probiotic bacterium with anticipated benefits similar to other clinically-used B. bifidum strains.
- Brand names
- Bifidobacterium bifidum BBi32
- Other names
- Bifidobacterium bifidum BBi32
Beyond the preview
Go deeper on Bifidobacterium bifidum BBi32.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium bifidum BBi32.